Korean Journal of Clinical Laboratory Science (대한임상검사과학회지)

Korean Society for Clinical Laboratory Science (대한임상검사과학회)
권호 표지
DOI QR코드

DOI QR Code

Status of Pathology Services and Molecular Pathology in Sub-Saharan Africa: Implications for Combating Breast Cancer

  • Received : 2023.04.29
  • Accepted : 2023.07.26
  • Published : 2023.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

African breast cancer patients benefit less from classical pathology services owing to the complex molecular and clinicopathological nature of the disease, poor quality of laboratory supplies, and shortage of experts in the field. This review presents evidence and confirms the need for improving anatomic pathology services in Africa. Peer-reviewed international journal articles available in Medline, Scopus, PubMed, and Google scholars, describing the status of pathology services in Africa, were included. Besides the late presentation of patients, anatomic pathology laboratories are accountable for the escalated mortality of breast cancer patients in several parts of Africa. Conversely, molecular diversity and biological heterogeneity of breast cancers, which disprove the one-size-fits-all therapeutic approach, have been reported from different parts of the continent. Irrespective of the geographical background, the choice of therapeutic options and predicting disease outcome depends on the right identification of the molecular signature of the cancer type. In conclusion, we propose that upgrading and integrating anatomic pathology with molecular diagnostic pathology is essential in order to provide better diagnostic results that will profoundly impact curbing mortality from breast cancers.

Keywords

References

  1. Leong AS, Zhuang Z. The changing role of pathology in breast cancer diagnosis and treatment. Pathobiology. 2011;78:99-114. https://doi.org/10.1159/000292644
  2. Haileselassie W, Kaba M, ArayaSellasie M, Mulugeta T, Labisso WL. Challenges and opportunities in cancer diagnosis In Ethiopia: in-depth exploration of practitioners' view. Int J Curr Res. 2017;9:54662-54668.
  3. Daramola AO, Banjo AA, Bennett A, Abdulkareem F, Shaaban AM. Breast cancer reporting in Lagos, Nigeria: implications for training and education in Africa. J Glob Oncol. 2016;2:397-402. https://doi.org/10.1200/jgo.2015.003079
  4. Elbireer AM, Jackson JB, Sendagire H, Opio A, Bagenda D, Amukele TK. The good, the bad, and the unknown: quality of clinical laboratories in Kampala, Uganda. PLoS One. 2013;8:e64661. https://doi.org/10.1371/journal.pone.0064661
  5. Fukayama M, Yoshino T, Nakamura S. Pathology in Germany and Finland: a brief report of the delegates of the Japanese Society of Pathology. Pathol Int. 2001;51:221-225. https://doi.org/10.1046/j.1440-1827.2001.01185.x
  6. Robboy SJ, Weintraub S, Horvath AE, Jensen BW, Alexander CB, Fody EP, et al. Pathologist workforce in the United States: I. Development of a predictive model to examine factors influencing supply. Arch Pathol Lab Med. 2013;137:1723-1732. https://doi.org/10.5858/arpa.2013-0200-oa
  7. Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:1194-1220. https://doi.org/10.1093/annonc/mdz173 Erratum in: Ann Oncol. 2019;30:1674. Erratum in: Ann Oncol. 2021;32:284.
  8. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424. https://doi.org/10.3322/caac.21492 Erratum in: CA Cancer J Clin. 2020;70:313.
  9. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015;385:977-1010. https://doi.org/10.1016/s0140-6736(14)62038-9 Erratum in: Lancet. 2015;385:946.
  10. Mishra SK, Tiwari BR, Yadav BK. Status of pathology professionals. J Nepal Health Res Counc. 2012;10:37-40.
  11. Haileselassie W, Mulugeta T, Tigeneh W, Kaba M, Labisso WL. The situation of cancer treatment in Ethiopia: challenges and opportunities. J Cancer Prev. 2019;24:33-42. https://doi.org/10.15430/jcp.2019.24.1.33
  12. Raab SS, Nakhleh RE, Ruby SG. Patient safety in anatomic pathology: measuring discrepancy frequencies and causes. Arch Pathol Lab Med. 2005;129:459-466. https://doi.org/10.5858/2005-129-459-psiapm
  13. Adeyi OA. Pathology services in developing countries-the West African experience. Arch Pathol Lab Med. 2011;135:183-186. https://doi.org/10.5858/2008-0432-ccr.1
  14. Atanda AT, Atanda JO. Audit of histopathology reports for breast cancer in Aminu Kano Teaching Hospital. West Afr J Med. 2010;29:174-177. https://doi.org/10.4314/wajm.v29i3.68216
  15. Nelson AM, Milner DA, Rebbeck TR, Iliyasu Y. Oncologic care and pathology resources in Africa: survey and recommendations. J Clin Oncol. 2016;34:20-26. https://doi.org/10.1200/jco.2015.61.9767
  16. Barton MB, Frommer M, Shafiq J. Role of radiotherapy in cancer control in low-income and middle-income countries. Lancet Oncol. 2006;7:584-595. https://doi.org/10.1016/s1470-2045(06)70759-8 Erratum in: Lancet Oncol. 2006;7:797.
  17. International Atomic Energy Agency (IAEA). Setting up a radiotherapy programme: clinical, medical physics, radiation protection and safety aspects. IAEA: 2008.
  18. Anim JT. The pathologist in Ghana and potential for research. Ghana Med J. 2018;52:103-111. https://doi.org/10.4314/gmj.v52i2.7
  19. Awadelkarim KD, Mohamedani AA, Barberis M. Role of pathology in sub-Saharan Africa: an example from Sudan. Pathol Lab Med Int. 2010;2:49-57. https://doi.org/10.2147/PLMI.S9779
  20. Rambau PF. Pathology practice in a resource-poor setting: Mwanza, Tanzania. Arch Pathol Lab Med. 2011;135:191-193. https://doi.org/10.5858/135.2.191
  21. Sayed S, Lukande R, Fleming KA. Providing pathology support in low-income countries. J Glob Oncol. 2015;1:3-6. https://doi.org/10.1200/jgo.2015.000943
  22. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-249. https://doi.org/10.3322/caac.21660
  23. Autier P, Boniol M, La Vecchia C, Vatten L, Gavin A, Hery C, et al. Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database. BMJ. 2010;341:c3620. https://doi.org/10.1136/bmj. c3620 Erratum in: BMJ. 2010;341:c4480.
  24. Ponti A, Anttila A, Ronco G, Senore C, Basu P, Segnan N et al. Cancer Screening in the European Union: report on the implementation of the Council Recommendation on cancer screening. Report. International Agency for Research on Cancer (IARC): Reprint 2017 May. p1-313.
  25. Duffy MJ, Harbeck N, Nap M, Molina R, Nicolini A, Senkus E, et al. Clinical use of biomarkers in breast cancer: updated guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer. 2017;75:284-298. https://doi.org/10.1016/j.ejca.2017.01.017
  26. Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J, et al. Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res. 2015;5:2929-2943.
  27. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752. https://doi.org/10.1038/35021093
  28. Shin BK, Lee Y, Lee JB, Kim HK, Lee JB, Cho SJ, et al. Breast carcinomas expressing basal markers have poor clinical outcome regardless of estrogen receptor status. Oncol Rep. 2008;19:617-625. https://doi.org/10.3892/or.19.3.617
  29. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24:2206-2223. https://doi.org/10.1093/annonc/mdt303
  30. Rhee J, Han SW, Oh DY, Kim JH, Im SA, Han W, et al. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer. 2008;8:307. https://doi.org/10.1186/1471-2407-8-307
  31. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005; 11:5678-5685. https://doi.org/10.1158/1078-0432.ccr-04-2421
  32. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14:1368-1376. https://doi.org/10.1158/1078-0432.ccr-07-1658
  33. Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF, et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol. 2004;203:661-671. https://doi.org/10.1002/path.1559
  34. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869-10874. https://doi.org/10.1073/pnas.191367098
  35. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006;7:96. https://doi.org/10.1186/1471-2164-7-96
  36. Eroles P, Bosch A, Perez-Fidalgo JA, Lluch A. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev. 2012;38:698-707. https://doi.org/10.1016/j.ctrv.2011.11.005
  37. Figueroa-Magalhaes MC, Jelovac D, Connolly R, Wolff AC. Treatment of HER2-positive breast cancer. Breast. 2014;23:128-136. https://doi.org/10.1016/j.breast.2013.11.011
  38. Stefan DC. Cancer care in Africa: an overview of resources. J Glob Oncol. 2015;1:30-36. https://doi.org/10.1200/jgo.2015.000406
  39. Howanitz PJ. Errors in laboratory medicine: practical lessons to improve patient safety. Arch Pathol Lab Med. 2005;129:1252-1261. https://doi.org/10.5858/2005-129-1252-eilmpl
  40. Alnegheimish NA, Alshatwi RA, Alhefdhi RM, Arafah MM, AlRikabi AC, Husain S. Molecular subtypes of breast carcinoma in Saudi Arabia. A retrospective study. Saudi Med J. 2016;37:506-512. https://doi.org/10.15537/smj.2016.5.15000
  41. Han Y, Li J. Sample types applied for molecular diagnosis of therapeutic management of advanced non-small cell lung cancer in the precision medicine. Clin Chem Lab Med. 2017;55:1817-1833. https://doi.org/10.1515/cclm-2017-0112
  42. Lara-Medina F, Perez-Sanchez V, Saavedra-Perez D, Blake-Cerda M, Arce C, Motola-Kuba D, et al. Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer. 2011;117:3658-3669. https://doi.org/10.1002/cncr.25961
  43. Shenkutie B, Mekonnen Y, Seifu D, Abebe E, Ergete W, Demie A, et al. Biological and clinicopathological characteristics of breast cancer at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. J Cancer Sci Ther. 2017;9:755-760. https://doi.org/10.4172/1948-5956.1000504
  44. Groner BL, Hynes NE. Breast cancer patients have greatly benefited from the progress in molecular oncology. PLoS Biol. 2016;14:e2000314. https://doi.org/10.1371/journal.pbio.2000314
  45. Shi Y, Jin J, Ji W, Guan X. Therapeutic landscape in mutational triple negative breast cancer. Mol Cancer. 2018;17:99. https://doi.org/10.1186/s12943-018-0850-9
  46. Adebamowo CA, Famooto A, Ogundiran TO, Aniagwu T, Nkwodimmah C, Akang EE. Immunohistochemical and molecular subtypes of breast cancer in Nigeria. Breast Cancer Res Treat. 2008;110:183-188. https://doi.org/10.1007/s10549-007-9694-5
  47. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, et al. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015;26:1533-1546. https://doi.org/10.1093/annonc/mdv221
  48. Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012;30:2615-2623. https://doi.org/10.1200/jco.2010.34.5579
  49. Masoud V, Pages G. Targeted therapies in breast cancer: new challenges to fight against resistance. World J Clin Oncol. 2017;8:120-134. https://doi.org/10.5306/wjco.v8.i2.120
  50. Masood S. Breast cancer subtypes: morphologic and biologic characterization. Womens Health (Lond). 2016;12:103-119. https://doi.org/10.2217/whe.15.99
  51. Raab SS, Grzybicki DM, Janosky JE, Zarbo RJ, Meier FA, Jensen C, et al. Clinical impact and frequency of anatomic pathology errors in cancer diagnoses. Cancer. 2005;104:2205-2213. https://doi.org/10.1002/cncr.21431
  52. Clary KM, Silverman JF, Liu Y, Sturgis CD, Grzybicki DM, Mahood LK, et al. Cytohistologic discrepancies: a means to improve pathology practice and patient outcomes. Am J Clin Pathol. 2002;117:567-573. https://doi.org/10.1309/0n45-cc0e-r802-d9ng
  53. Amirikia KC, Mills P, Bush J, Newman LA. Higher population-based incidence rates of triple-negative breast cancer among young African-American women: implications for breast cancer screening recommendations. Cancer. 2011;117:2747-2753. https://doi.org/10.1002/cncr.25862
  54. Ly M, Antoine M, Dembele AK, Levy P, Rodenas A, Toure BA, et al. High incidence of triple-negative tumors in sub-saharan Africa: a prospective study of breast cancer characteristics and risk factors in Malian women seen in a Bamako university hospital. Oncology. 2012;83:257-263. https://doi.org/10.1159/000341541
  55. Adisa CA, Eleweke N, Alfred AA, Campbell MJ, Sharma R, Nseyo O, et al. Biology of breast cancer in Nigerian women: a pilot study. Ann Afr Med. 2012;11:169-175. https://doi.org/10.4103/1596-3519.96880
  56. Stark A, Kleer CG, Martin I, Awuah B, Nsiah-Asare A, Takyi V, et al. African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study. Cancer. 2010;116:4926-4932. https://doi.org/10.1002/cncr.25276